| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ... The Lancet 389 (10088), 2492-2502, 2017 | 3941 | 2017 |
| Cabozantinib in patients with advanced and progressing hepatocellular carcinoma GK Abou-Alfa, T Meyer, AL Cheng, AB El-Khoueiry, L Rimassa, BY Ryoo, ... New England Journal of Medicine 379 (1), 54-63, 2018 | 2081 | 2018 |
| Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ... Jama 317 (23), 2392-2401, 2017 | 825 | 2017 |
| Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma M Javle, M Lowery, RT Shroff, KH Weiss, C Springfeld, MJ Borad, ... Journal of Clinical Oncology 36 (3), 276, 2018 | 670 | 2018 |
| SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and … E Ben-Josef, KA Guthrie, AB El-Khoueiry, CL Corless, MM Zalupski, ... Journal of Clinical Oncology 33 (24), 2617, 2015 | 384 | 2015 |
| Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline RT Shroff, EB Kennedy, M Bachini, T Bekaii-Saab, C Crane, J Edeline, ... Journal of Clinical Oncology 37 (12), 1015-1027, 2019 | 382 | 2019 |
| AKT inhibition in solid tumors with AKT1 mutations DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ... Journal of Clinical Oncology 35 (20), 2251, 2017 | 284 | 2017 |
| Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. AB El-Khoueiry, I Melero, TS Crocenzi, TH Welling, TC Yau, W Yeo, ... Journal of Clinical Oncology 33 (18_suppl), LBA101-LBA101, 2015 | 269 | 2015 |
| Nivolumab (NIVO)+ ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. T Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ... Journal of Clinical Oncology 37 (15_suppl), 4012-4012, 2019 | 246 | 2019 |
| First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma AX Zhu, PJ Gold, AB El-Khoueiry, TA Abrams, H Morikawa, N Ohishi, ... Clinical cancer research 19 (4), 920-928, 2013 | 199 | 2013 |
| SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma AB El-Khoueiry, CJ Rankin, E Ben-Josef, HJ Lenz, PJ Gold, RD Hamilton, ... Investigational new drugs 30, 1646-1651, 2012 | 175 | 2012 |
| Impact of sex on the survival of patients with hepatocellular carcinoma: a surveillance, epidemiology, and end results analysis D Yang, DL Hanna, J Usher, J LoCoco, P Chaudhari, HJ Lenz, ... Cancer 120 (23), 3707-3716, 2014 | 151 | 2014 |
| Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006 R Govindarajan, J Adusumilli, DL Baxter, A El-Khoueiry, SI Harik Journal of Clinical Oncology 24 (28), e48-e48, 2006 | 137 | 2006 |
| Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer … G Lurje, F Nagashima, W Zhang, D Yang, HM Chang, MA Gordon, ... Clinical Cancer Research 14 (23), 7884-7895, 2008 | 132 | 2008 |
| S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma AB El-Khoueiry, C Rankin, AB Siegel, S Iqbal, IY Gong, KC Micetich, ... British journal of cancer 110 (4), 882-887, 2014 | 129 | 2014 |
| Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review DA Etzioni, AB El‐Khoueiry, RW Beart Jr Cancer 113 (12), 3279-3289, 2008 | 125 | 2008 |
| A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. AB El-Khoueiry, Y Ning, D Yang, S Cole, M Kahn, M Zoghbi, J Berg, ... Journal of Clinical Oncology 31 (15_suppl), 2501-2501, 2013 | 123 | 2013 |
| Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III … GK Abou-Alfa, T Meyer, AL Cheng, AB El-Khoueiry, L Rimassa, BY Ryoo, ... Journal of Clinical Oncology 36 (4_suppl), 207-207, 2018 | 122 | 2018 |
| Nivolumab in sorafenib-naive and-experienced patients with advanced hepatocellular carcinoma: CheckMate 040 study TS Crocenzi, AB El-Khoueiry, T Yau, I Melero, B Sangro, M Kudo, C Hsu, ... J Clin Oncol 35 (suppl 15), 4013, 2017 | 117 | 2017 |
| Common cancer stem cell gene variants predict colon cancer recurrence A Gerger, W Zhang, D Yang, P Bohanes, Y Ning, T Winder, MJ LaBonte, ... Clinical Cancer Research 17 (21), 6934-6943, 2011 | 108 | 2011 |
